AR059280A1 - Compuestos heterociclicos que contienen nitrogeno - Google Patents
Compuestos heterociclicos que contienen nitrogenoInfo
- Publication number
- AR059280A1 AR059280A1 ARP070100427A ARP070100427A AR059280A1 AR 059280 A1 AR059280 A1 AR 059280A1 AR P070100427 A ARP070100427 A AR P070100427A AR P070100427 A ARP070100427 A AR P070100427A AR 059280 A1 AR059280 A1 AR 059280A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- benzoxazin
- dihydro
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- -1 nitrogen heterocyclic compound Chemical class 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- MSFQEZBRFPAFEX-UHFFFAOYSA-N 4-methoxybenzenesulfonamide Chemical compound COC1=CC=C(S(N)(=O)=O)C=C1 MSFQEZBRFPAFEX-UHFFFAOYSA-N 0.000 abstract 1
- HRVRHURTBLTVRC-UHFFFAOYSA-N 6-bromonaphthalene-2-sulfonamide Chemical compound C1=C(Br)C=CC2=CC(S(=O)(=O)N)=CC=C21 HRVRHURTBLTVRC-UHFFFAOYSA-N 0.000 abstract 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000016998 Conn syndrome Diseases 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 206010039808 Secondary aldosteronism Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 239000002395 mineralocorticoid Substances 0.000 abstract 1
- LSFAMAAVDNXAIW-UHFFFAOYSA-N n-(4-benzyl-3-oxo-1,4-benzoxazin-7-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(N(CC=2C=CC=CC=2)C(=O)CO2)C2=C1 LSFAMAAVDNXAIW-UHFFFAOYSA-N 0.000 abstract 1
- HVHHQCZXBAOBPO-UHFFFAOYSA-N n-[2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazin-6-yl]methanesulfonamide Chemical compound C12=CC(NS(C)(=O)=O)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] HVHHQCZXBAOBPO-UHFFFAOYSA-N 0.000 abstract 1
- MISLTYDUFRKZSH-UHFFFAOYSA-N n-[4-[[4-[(2-fluorophenyl)methyl]-3-oxo-1,4-benzoxazin-7-yl]sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=CC=C(N(CC=2C(=CC=CC=2)F)C(=O)CO2)C2=C1 MISLTYDUFRKZSH-UHFFFAOYSA-N 0.000 abstract 1
- GFLWSZQJMGOEPH-UHFFFAOYSA-N n-[4-[[4-[(4-fluorophenyl)methyl]-3-oxo-1,4-benzoxazin-7-yl]sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=CC=C(N(CC=2C=CC(F)=CC=2)C(=O)CO2)C2=C1 GFLWSZQJMGOEPH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000013846 primary aldosteronism Diseases 0.000 abstract 1
- DWHIGANEUNBVPB-UHFFFAOYSA-N quinoline-5-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=CC=CC2=N1 DWHIGANEUNBVPB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La presente reivindica un compuesto heterocíclico nitrogenado, util como un agente que modula el receptor mineralcorticoide y una composicion farmacéutica en base al compuesto. Los compuestos son utiles en la prevencion y tratamiento de enfermedades cardiovasculares o enfermedades endocrinas que incluyen aldosteronismo primario/secundario. Reivindicacion 1: Un compuesto de la siguiente formula (1) donde el anillo A es un anillo de benceno que tiene en forma opcional un sustituyentes(s) diferente a R1 o un anillo heterocíclico aromático de 6 miembros que contiene N que tiene en forma opcional un sustituyente(s) diferente a R1; R1 es un grupo de la formula: RaSO2NH-, RaSO2NH-CH2- o (Rb)(Rc)NSO2-, Ra es un grupo alquilo, cicloalquilo, amino sustituido en forma opcional con un grupo(s) alquilo, un grupo arilo sustituido en forma opcional, o un heteroarilo sustituido en forma opcional, Rb y Rc son iguales o diferentes y son cada uno un átomo de hidrogeno, un grupo alquilo o un grupo cicloalquilo, R2 y R3 son iguales o diferentes y son cada uno un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo sustituido en forma opcional, un grupo alquenilo, carboxilo, alcoxicarbonilo, carbamoilo sustituido en forma opcional o un grupo arilo sustituido en forma opcional, o R2 y R3 se unen entre sí con el átomo de carbono contiguo para formar un grupo cíclico saturado o no saturado (conteniendo dicho grupo cíclico en forma opcional uno o dos heteroátomos, que pueden ser iguales o diferentes, seleccionados de un átomo de oxígeno, azufre y nitrogeno), X es un átomo de oxígeno, azufre, un grupo metileno o un grupo de la formula: -NR4-, R4 es un átomo de hidrogeno, un grupo alquilo, aralquilo sustituido en forma opcional un grupo acilo, Y es un grupo de la formula: -C(=O)-, -C(=S)- o -CH(R5)-; R5 es un átomo de hidrogeno, un grupo alquilo o un grupo arilo sustituido en forma opcional, Ar es un grupo arilo sustituido en forma opcional o un grupo heteroarilo sustituido en forma opcional, y Q es un enlace simple, un grupo alquileno o un grupo alquenileno, o una sal aceptable para uso farmacéutico del mismo, que excluye N-(4-bencil-3-oxo-3,4-dihidro-2H-1,4-benzoxazin-7-il) (p-toluen- sulfonamida); N-[4-(2-fluorobencil)-3-oxo-3,4-dihidro-2H-1,4-benzoxazin-7-il] [4-(N-acetilamino)bencensulfonamida]; N-[4-(4-fluorobencil)-3-oxo-3,4-dihidro-2H-1,4-benzoxazin-7-il] [4-(N-acetilamino)bencensulfonamida]; N-[4-(7-amidinonaftalen-2- il)metii-3-oxo-3,4- dihidro-2H-1,4-benzoxazin-7-il]bencensulfonamida; N-[4-(7-amidinonaftalen-2-il)metil-3-oxo-3,4- dihidro-2H-1,4-benzoxazin-7-il] (p-metoxifenil-sulfonamida); N-[4-(7-amidinonaftalen-2-il)metii-3-oxo-3,4-dihidro-2H-1,4-benzoxazin-7- il](6-bromonaftalen-2- il) sulfonamida; N-[4-(7-amidinonaftalen-2-il)metil-3-oxo-3,4-dihidro-2H-1,4-benzoxazin-7-il] (5-quinolilsulfonamida); y N-[2,2-dimetil-4-(1-oxidopiridin-2-il)-3,4-dihidro-2H-1,4-benzoxazin-6-il] metansulfonamida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006025403 | 2006-02-02 | ||
| JP2006275917 | 2006-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059280A1 true AR059280A1 (es) | 2008-03-19 |
Family
ID=38110055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100427A AR059280A1 (es) | 2006-02-02 | 2007-02-01 | Compuestos heterociclicos que contienen nitrogeno |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7998956B2 (es) |
| EP (1) | EP1984345B9 (es) |
| KR (1) | KR101046548B1 (es) |
| AR (1) | AR059280A1 (es) |
| AT (1) | ATE522511T1 (es) |
| AU (1) | AU2007210424C1 (es) |
| BR (1) | BRPI0707491B8 (es) |
| CA (1) | CA2636985C (es) |
| DK (1) | DK1984345T3 (es) |
| MX (1) | MX285869B (es) |
| PH (1) | PH12008501738B1 (es) |
| PL (1) | PL1984345T3 (es) |
| PT (1) | PT1984345E (es) |
| RU (1) | RU2398769C2 (es) |
| TW (1) | TWI385161B (es) |
| WO (1) | WO2007089034A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940900B2 (en) * | 2007-02-28 | 2015-01-27 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| EP2266989B1 (en) * | 2008-03-31 | 2015-09-02 | C&c Research Laboratories | Heterocyclic derivatives |
| US20090253693A1 (en) * | 2008-04-07 | 2009-10-08 | Dmitry Koltun | 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| LT2794600T (lt) | 2011-12-22 | 2018-02-26 | Novartis Ag | 2,3-dihidro-benzo[1,4]oksazino dariniai ir giminingi junginiai kaip fosfoinozitido-3 kinazės (pi3k) inhibitoriai, skirti gydymui, pavyzdžiui, reumatoidinio artrito |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| EP2883870B8 (en) * | 2012-08-08 | 2019-01-23 | Mitsubishi Tanabe Pharma Corporation | Method for producing 1,4-benzoxazine compound |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| WO2015074081A1 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
| SI3071203T1 (sl) | 2013-11-18 | 2021-07-30 | Forma Therapeutics, Inc. | Sestavki tetrahidrokinolina, kot zaviralci BET bromodomene |
| CN103694137A (zh) * | 2013-12-06 | 2014-04-02 | 常州工程职业技术学院 | 一种2-氟-4-硝基苯甲腈的清洁生产方法 |
| EA029518B1 (ru) | 2014-06-30 | 2018-04-30 | Астразенека Аб | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора |
| WO2017064121A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| WO2018019843A1 (en) | 2016-07-26 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| TWI603962B (zh) | 2016-09-10 | 2017-11-01 | 國立清華大學 | 含硫噁嗪化合物及其合成方法 |
| BR112019005456A2 (pt) | 2016-09-27 | 2019-06-04 | Mitsubishi Tanabe Pharma Corp | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica |
| EP3525779B1 (de) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone |
| EP3525778A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2018149754A1 (en) | 2017-02-16 | 2018-08-23 | Basf Se | Pyridine compounds |
| WO2018153898A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
| DE102017008472A1 (de) | 2017-09-08 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten |
| AR117988A1 (es) | 2019-02-05 | 2021-09-08 | Mitsubishi Tanabe Pharma Corp | Medicamento para profilaxis o tratamiento para la fibrosis pulmonar |
| US20230015691A1 (en) | 2019-11-26 | 2023-01-19 | Mitsubishi Tanabe Pharma Corporation | Prophylactic or therapeutic agent for non-alcoholic steatohepatitis in humans |
| US20230151425A1 (en) | 2020-03-11 | 2023-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW224941B (es) | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
| CN1029479C (zh) | 1989-11-08 | 1995-08-09 | 山之内制药株式会社 | 新型苯并噁嗪衍生物的制备方法 |
| US5420126A (en) * | 1989-11-08 | 1995-05-30 | Yamanouchi Pharmaceutical Co., Ltd. | 3,4-dihydro-2H-1,4-benzoxazine derivatives and pharmaceutical compositions containing the same |
| US5696117A (en) | 1995-11-07 | 1997-12-09 | Ortho Pharmaceutical Corporation | Benzoxazine antimicrobial agents |
| DE19727117A1 (de) | 1997-06-26 | 1999-01-07 | Boehringer Ingelheim Pharma | Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US6358948B1 (en) * | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6509334B1 (en) * | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6498154B1 (en) * | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| AU2001236606A1 (en) * | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa |
| UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| PL377770A1 (pl) * | 2002-11-08 | 2006-02-20 | F. Hoffmann-La Roche Ag | Podstawione benzoksazynony i ich zastosowanie |
| JP2007500253A (ja) * | 2003-01-22 | 2007-01-11 | イーライ リリー アンド カンパニー | ステロイドホルモン核内受容体のインドール誘導体モジュレーター |
| CA2549053C (en) | 2003-12-19 | 2012-08-28 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
| JPWO2006077821A1 (ja) * | 2005-01-19 | 2008-06-19 | 大日本住友製薬株式会社 | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
-
2007
- 2007-01-22 TW TW096102259A patent/TWI385161B/zh not_active IP Right Cessation
- 2007-02-01 PL PL07713915T patent/PL1984345T3/pl unknown
- 2007-02-01 US US12/162,779 patent/US7998956B2/en active Active
- 2007-02-01 AR ARP070100427A patent/AR059280A1/es active IP Right Grant
- 2007-02-01 PT PT07713915T patent/PT1984345E/pt unknown
- 2007-02-01 DK DK07713915.2T patent/DK1984345T3/da active
- 2007-02-01 KR KR1020087019085A patent/KR101046548B1/ko not_active Expired - Fee Related
- 2007-02-01 WO PCT/JP2007/052165 patent/WO2007089034A1/en not_active Ceased
- 2007-02-01 BR BRPI0707491A patent/BRPI0707491B8/pt not_active IP Right Cessation
- 2007-02-01 RU RU2008135468/04A patent/RU2398769C2/ru active
- 2007-02-01 CA CA2636985A patent/CA2636985C/en active Active
- 2007-02-01 AU AU2007210424A patent/AU2007210424C1/en not_active Ceased
- 2007-02-01 AT AT07713915T patent/ATE522511T1/de active
- 2007-02-01 EP EP07713915A patent/EP1984345B9/en active Active
-
2008
- 2008-07-29 PH PH12008501738A patent/PH12008501738B1/en unknown
- 2008-08-01 MX MX2008010022A patent/MX285869B/es active IP Right Grant
-
2011
- 2011-06-24 US US13/167,986 patent/US8188073B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW200800926A (en) | 2008-01-01 |
| DK1984345T3 (da) | 2011-12-12 |
| AU2007210424A1 (en) | 2007-08-09 |
| KR20080083698A (ko) | 2008-09-18 |
| PT1984345E (pt) | 2011-09-08 |
| MX285869B (en) | 2011-04-19 |
| WO2007089034A1 (en) | 2007-08-09 |
| EP1984345B9 (en) | 2012-03-21 |
| AU2007210424B2 (en) | 2010-07-15 |
| EP1984345A1 (en) | 2008-10-29 |
| BRPI0707491A2 (pt) | 2011-05-03 |
| TWI385161B (zh) | 2013-02-11 |
| BRPI0707491B8 (pt) | 2021-05-25 |
| AU2007210424C1 (en) | 2010-11-18 |
| PL1984345T3 (pl) | 2012-01-31 |
| CA2636985C (en) | 2011-08-16 |
| US20090023716A1 (en) | 2009-01-22 |
| US7998956B2 (en) | 2011-08-16 |
| EP1984345B1 (en) | 2011-08-31 |
| KR101046548B1 (ko) | 2011-07-05 |
| BRPI0707491B1 (pt) | 2019-12-10 |
| CA2636985A1 (en) | 2007-08-09 |
| RU2008135468A (ru) | 2010-03-10 |
| US8188073B2 (en) | 2012-05-29 |
| RU2398769C2 (ru) | 2010-09-10 |
| US20110251185A1 (en) | 2011-10-13 |
| ATE522511T1 (de) | 2011-09-15 |
| PH12008501738B1 (en) | 2013-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059280A1 (es) | Compuestos heterociclicos que contienen nitrogeno | |
| AR061918A1 (es) | Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| AR068014A1 (es) | Derivados de pirimidin-2-il-amina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la cinasa. | |
| AR059339A1 (es) | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| AR064521A1 (es) | Activador de glucoquinasa | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
| PE20020566A1 (es) | DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| PE20020589A1 (es) | 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas | |
| PE20200608A1 (es) | Nuevos derivados de azaquinolina | |
| AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| PE72899A1 (es) | Derivados sulfonamida | |
| AR029616A1 (es) | Compuestos derivados de 3-fenil-piridina, su uso, un proceso para prepararlos y medicamentos que los contienen | |
| PE20170323A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| AR055959A1 (es) | Derivados espiro para la modulacion de actividad de crth2 | |
| AR079236A1 (es) | Derivados de ciclohexano y usos de los mismos | |
| AR070274A1 (es) | Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| PE20091102A1 (es) | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 | |
| AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |